Fabian Finkelmeier

Goethe University Frankfurt — Germany

Medicine · Health Sciences

35h-index5.6kcitations228works3.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(61), Liver Disease Diagnosis and Treatment(41), Cholangiocarcinoma and Gallbladder Cancer Studies(40), Cancer Immunotherapy and Biomarkers(30), Hepatitis C virus research(29)

Publications227 total

Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab
Targeted Oncology·2026
Safety, pharmacokinetics, and preliminary efficacy of VS-01, an intraperitoneal liposomal infusion, in patients with decompensated liver cirrhosis, ascites, and covert hepatic encephalopathy: a phase 1b, first-in-human, open-label, non-randomised, single ascending and multiple dose study
˜The œLancet. Gastroenterology & hepatology·2026Open Access
Long-Term Outcomes of Transarterial Chemoembolization for Intrahepatic Cholangiocarcinoma: Overall Survival and Tumor Response
Cureus·2026Open Access
Evaluation of early C-reactive protein kinetics as an early response marker in biliary tract cancer patients treated with combined chemoimmunotherapy.
Journal of Clinical Oncology·2026
Co-administered internalizing RGD peptide boosts anti-PD-L1 therapy in hepatocellular carcinoma
JHEP Reports·2026Open Access
Co-administered iRGD boosts anti-PD-L1 therapy in hepatocellular carcinoma
Zeitschrift für Gastroenterologie·2026
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab
European Journal of Cancer·2025
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Journal for ImmunoTherapy of Cancer·2025Open Access
104eP A new prognostic index for patients with advanced biliary tract cancer treated with cisplatin, gemcitabine and durvalumab
Annals of Oncology·2025
Perorale endoskopische Stufenmyotomie in Achalasie Typ II erhöht die Rate an propulsiver Peristaltik nach Intervention
Zeitschrift für Gastroenterologie·2025
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy
Oncology·2025· 2 cited
Negative impact of corticosteroid use on outcome in patients with advanced <scp>BTCs</scp> treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population
International Journal of Cancer·2025Open Access
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population
JNCI Journal of the National Cancer Institute·2025· 1 citedOpen Access
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The <scp>MAGIC</scp>‐D Index
Liver International·2025· 4 citedOpen Access
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population
Seminars in Oncology·2025· 2 citedOpen Access
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study
International Journal of Cancer·2025· 1 citedOpen Access
LBP-029-YI Spatial transcriptomics of the tumor microenvironment discriminates inflamed tumors responsive or resistant to atezolizumab + bevacizumab in patients with advanced HCC
Journal of Hepatology·2025Open Access
WED-102-YI Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapy
Journal of Hepatology·2025
Risk Factors for Premature Exchange of Percutaneous Biliary Drainage in Benign and Malignant Biliary Strictures: A Retrospective Single-Center Study
Visceral Medicine·2025Open Access
Percutaneous endoscopic gastrostomy by “push” method with gastropexy or “pull-through” method: is there a difference regarding peristomal infections?
Endoscopy·2025
page 1 of 12Next →

Frequent Co-authors

Oliver Waidmann(23), Stefan Zeuzem(18), Vera Himmelsbach(13), Masatoshi Kudo(10), Gianluca Masi(10), Jörg Trojan(10), Hong Jae Chon(9), Caterina Vivaldi(9), Matthias Pinter(8), Lorenza Rimassa(8), Bernhard Scheiner(8), Arndt Weinmann(8), Ho Yeong Lim(8), Bernd Kronenberger(8), Albrecht Piiper(8), Andrea Casadei‐Gardini(8), Margherita Rimini(8), Mario Scartozzi(8), Tiziana Pressiani(7), Jean‐François Dufour(7)